The potential role of neutrophil trogocytosis and G-CSF in the loss of HER2 expression
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F19%3A10399303" target="_blank" >RIV/00064203:_____/19:10399303 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/19:10399303 RIV/00216208:11130/19:10399303
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=.xuqSXq78J" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=.xuqSXq78J</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s10549-019-05386-7" target="_blank" >10.1007/s10549-019-05386-7</a>
Alternative languages
Result language
angličtina
Original language name
The potential role of neutrophil trogocytosis and G-CSF in the loss of HER2 expression
Original language description
In HER2-positive breast cancer (BC), the standard treatment consists of neoadjuvant sequential chemotherapy, HER2-targeted therapy, surgery, and, if indicated, radiotherapy and/or hormonal therapy. Trastuzumab, a recombinant antibody targeting HER2, has significantly extended the overall survival of BC patients and remains clinically reliable treatment. The 5-year survival, when following the standard treatment protocol, including HER2-targeted therapy, leads to a favorable prognosis with a 5-year survival rate around 75%. Improved overall survival (OS) was reported in BC patients when trastuzumab was administered in both the neoadjuvant and adjuvant period rather than in the adjuvant period alone. Thus, trastuzumab-containing neoadjuvant therapy is currently the standard of care.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Breast Cancer: Research and Treatment
ISSN
0167-6806
e-ISSN
—
Volume of the periodical
178
Issue of the periodical within the volume
1
Country of publishing house
US - UNITED STATES
Number of pages
2
Pages from-to
247-248
UT code for WoS article
000491935000026
EID of the result in the Scopus database
2-s2.0-85073182801